Research/Studies

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Sleep Pharmaceuticals Narcolepsy Research/Studies

Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Alkermes plc today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as […]

Pediatrics Mental & Behavioral Health Research/Studies

Sleep To Live Well Foundation Launches With Groundbreaking Sleep Wellness Report

The Sleep To Live Well Foundation issues an urgent warning in its groundbreaking 2025 State of Sleep Wellness Report, titled “THE SILENT EPIDEMIC: How Lack of Sleep Endangers Over Half of All Americans and Threatens Everyone.” The report unveils the Foundation’s initiatives to address this insufficient sleep crisis with Sleep Wellness—a holistic approach to […]

HST Home Sleep Testing
SleepWorld Magazine Home Sleep Testing (HST) Obstructive Sleep Apnea Research/Studies

The Accuracy of Home Sleep Testing

Home sleep tests (HSTs) have emerged as a convenient and cost-effective alternative to traditional in-lab polysomnography (PSG) for diagnosing sleep disorders, particularly obstructive sleep apnea (OSA). Over the years, HST technology has advanced significantly, leading to improvements in accuracy and reliability. In this article, I will explore the accuracy of […]

apnimed SynAIRgy Phase 3 Results
Obstructive Sleep Apnea Research/Studies Sleep Pharmaceuticals

Apnimed Announces SynAIRgy Phase 3 Results

Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]